The top 100 stock
market authors
selected for publication
market authors
selected for publication
Alkermes Inc. (ALKS) ()
|
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: |
Articles on Alkermes Inc. (ALKS) by latest | most commented
- Smaller Pharma Wins the 'Most Valuable' Race
- 74 Solid, Growing Companies in a Recession
- 30 Possible Pandemic Profit Plays: Bullish Biotech and Drug Stocks to Watch
- Aradigm: Hard to Value, But Significant Upside
- Biotech Opportunities: Look for Decent Pipeline, Big Pharma Partnerships
- Alkermes Outlook Remains Bleak
- Wall Street Breakfast: Must-Know News
- FDA Calendar Updates: Acusphere, AspenBio, Alkermes
- Who Will Win the Amylin Battle?
- Early Filing for Byetta: Will It Become a Blockbuster?
- FDA Calendar Updates: Amylin, Alkermes, Eli Lilly, Cell Therapeutics
- FDA, Clinical Trial Calendar Updates: Acorda, Alkermes, GTx
- 15 'Bathwater Babies' and 20 'Dogs with Fleas' for the Week
- Which Diabetes Drugs Will Win Out?
- Merck's Jumpin' Januvia Gets a Reprieve
- Monthly Big 5: Stocks Worth Watching
- Updated FDA Calendar: Cypress Bioscience Looks Like a Buy
- Eli Lilly's CEO: 'Ludicrous' Stock Price
- Nine Pharma Predictions for 2009
- Wall Street Breakfast: Must-Know News
- Recessionary Equity Strategies: Still Going for Growth
- Tuesday Options Update: ADM, KGC, AMLN, ALKS, SOLF, HLF & EXPD
- Why I'm Buying Amylin Now
- So Much for the Summer Doldrums with Drugmakers
- BioMarin, Myriad, and Regeneron Show a Quiet Strength
- Is Lilly and Amylin's Byetta Better?
- Analyst Notes: Lilly Gets A Lift, Pfizer Goes Pfft
- Biotech Sector Continues to Outperform
- Wall Street Breakfast: Must-Know News
- Generex Biotechnology: Oral-lyn Buccal Insulin Takes Center Stage
- Inhaled Insulin: Eli Lilly On Its 'Last Breath'?
- Alkermes Should Profit From Lilly's Delayed Drug
- Alkermes, Lilly, Mannkind: Inhaled Insulin Just Got Interesting
- Eat It, Breathe It, Soak in It? Drug Administration Gets Tricky
- Did Inside Connections Influence Glaxo's Bid For Reliant?
- Is A New Blockbuster Drug In The Works For Alkermes?
- Loeb's Third Point Releases 13F Filing, Shows a Number of New Positions
- Biotech In Review: Dyax Jumps On Positive Data
- Biotech Day In Review: Roche Picks Up Antibody Firm For $56.5 Million
- Biotech Day in Review: Novartis Gets Approval for Hypertensive Drug Tekturna
- Biotech Stocks Review: Seattle Genetics Sells Cancer Drug To Genentech
-
The Seeking Alpha 100
See all
Seeking Alpha 100 » -
Fastest Climbers
Authors with the largest
increase in followers
in the last 7 days-
1
David Fry
-
2
Philip Davis
-
3
Bill Gross
-
4
Tyler Durden
-
5
TraderMark
Fastest Climbers » -
1
-
Top Commenters
Top commenters,See all
as ranked by their peers
Top Commenters » -
Top Instabloggers
The 100 most activeSee all
Instabloggers.
Top Instabloggers » -
Top StockTalkers
TopSee all
StockTalkers.
Top StockTalkers »
